PharmaEssentia

6446.TWApproved

Taipei, TaiwanFounded 2003pharmaessentia.com

Founded in 2003 by Taiwanese-American executives and scientists, PharmaEssentia has grown from a small startup in Taipei's Nangang Software Park into a publicly traded global biopharmaceutical company (TWSE: 6446). The company operates world-class cGMP biologics facilities and has established a strong international presence with subsidiaries across the US, Europe, Japan, and Asia. PharmaEssentia's innovative approach to redesigning interferon therapies has resulted in breakthrough treatments for rare blood cancers, with BESREMi® representing a paradigm shift in MPN treatment. The company continues to expand its pipeline and global reach while maintaining its commitment to transforming treatment paradigms for patients with serious hematologic diseases.

Market Cap

$7.4B

Founded

2003

Focus

Biologics

6446.TW · Stock Price

USD 640.00+382.83 (+148.86%)

Historical price data

AI Company Overview

Technology Platform

Innovative redesign of interferon therapies through fusion of biology and synthetic organic chemistry, focusing on transforming risk/benefit profiles of existing therapies to unlock new treatment paradigms for rare blood cancers and other serious diseases.

Pipeline Snapshot

32 drugs in pipeline, 10 in Phase 3

Drug	Indication	Stage
Ropeginterferon alfa-2b	Polycythemia Vera	Approved
P1101 (Ropeginterferon alfa-2b)	Polycythemia Vera (PV)	Phase 3
Ropeginterferon alfa-2b	Primary Myelofibrosis	Phase 3
P1101 (Ropeginterferon alfa-2b-njft) + Ropeginterferon alfa-2b-njft (P1101)	Polycythemia Vera	Phase 3
Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen	Polycythemia Vera	Phase 3

FDA Approved Drugs

BESREMIBLANov 12, 2021

Opportunities

Significant expansion potential through the ongoing SURPASS ET Phase 3 trial for essential thrombocythemia, which could substantially broaden the addressable market beyond polycythemia vera.

Global market expansion continues with recent regulatory approvals and the company's established manufacturing and commercial infrastructure provides a strong foundation for pipeline growth.

Risk Factors

Concentration in the specialized MPN treatment space creates dependency on this therapeutic area, while competition from larger pharmaceutical companies entering rare hematology could impact market position.

Regulatory complexities and clinical trial uncertainties remain inherent risks in the biopharmaceutical industry.

Competitive Landscape

PharmaEssentia maintains a unique first-mover advantage with BESREMi® as the world's first FDA-approved interferon therapy for polycythemia vera. The company has established strong differentiation through its innovative approach to redesigning interferons, competing in the specialized rare hematology space rather than broader oncology markets.

Publications

Patents

Pipeline

FDA Approvals